Enlivex Ltd.
$0.73
+0.0180 (2.54%)
Join the Enlivex Ltd. Investor Community
Get the latest news and company updates delivered straight to your inbox. Subscribe for free to stay ahead of the story and follow Enlivex Ltd. as new developments unfold.
Company Overview
Enlivex operates a dual-strategy corporate structure that combines clinical development in quality longevity therapeutics with a digital asset treasury strategy centered on the Rain prediction markets protocol.
The first strategy of this model is Allocetra™, Enlivex’s macrophage reprogramming immunotherapy platform. Allocetra™ is designed to restore immune balance by reprogramming dysregulated macrophages back to their homeostatic state. The therapy is being developed to address inflammatory and degenerative conditions associated with aging, including knee osteoarthritis and additional high-need indications. Positive clinical data in knee osteoarthritis have demonstrated meaningful reductions in pain and improvements in function across treated patients.
The second strategy of the Enlivex model is its RAIN-based digital asset treasury strategy. Through a $212 million private placement, Enlivex established the first public company treasury strategy centered on a decentralized prediction markets protocol. Rain functions as a forecasting infrastructure where decentralized markets resolve real-world outcomes through token-based economic mechanisms, including a buyback-and-burn structure. Allocetra™ provides the biological value floor through clinical development in longevity therapeutics, while the RAIN treasury operates as the financial growth driver, giving Enlivex exposure to the expanding decentralized forecasting ecosystem through a Nasdaq-listed structure.
Value Proposition
Enlivex offers a differentiated, dual-strategy value creation model that converges clinical-stage quality longevity science with the emerging prediction-markets economy. Through this structure, Enlivex combines the advancement of Allocetra™, its novel macrophage reprogramming immunotherapy, with a strategic digital asset treasury centered on the RAIN protocol.
The Company’s RAIN-based treasury strategy provides investors with compliant public-market exposure to the rapidly expanding decentralized prediction-markets ecosystem. In 2025, this strategy generated $1.23 billion in net income and $25.48 in diluted EPS, driven by appreciation in treasury and treasury-related assets, and resulted in a year-end treasury base of $2.31 billion. Supported by an exclusive option to acquire up to $918M of RAIN at a fixed price of $0.0033 through December 31, 2027, this active treasury model is designed to systematically expand long-term RAIN holdings through staking, governance participation, and disciplined capital allocation.
At the same time, Enlivex continues advancing Allocetra™, a universal, off-the-shelf cell therapy designed to restore macrophage homeostasis and address major inflammatory and degenerative diseases associated with aging. Positive clinical data in knee osteoarthritis—including meaningful pain reduction and functional improvement across patient subgroups—along with development programs in basal thumb OA, TMJ OA, and psoriatic arthritis, highlights a broad multi-billion-dollar market opportunity.
With an accomplished leadership team, strengthened balance sheet, and two non-correlated strategies of growth—longevity science innovation and a prediction-markets treasury—Enlivex represents a unique opportunity for investors seeking asymmetric upside at the intersection of next-generation immunotherapy and decentralized financial infrastructure.
Investor Presentation
Investment Highlights
Transformational Digital Asset Treasury Strategy
- First public company to adopt corporate treasury strategy on the RAIN token, a decentralized, permissionless predictions and options protocol with AI-resolved markets and a deflationary buyback-and-burn mechanism
- Strategy generated FY 25 net income of $1.23B and $25.48 diluted EPS
- Exclusive option to acquire up to $918M of RAIN at $0.0033 through Dec. 31, 2027; fixed price option creates substantial asymmetric upside as Rain adoption accelerates
- Active, yield-generating treasury strategy designed to grow RAIN holdings through staking, governance participation, and treasury management
Dual-Strategy Corporate Model
- Dual-strategy structure combining longevity therapeutics development with a digital asset treasury
- Allocetra™ provides the scientific and clinical value floor
- RAIN treasury provides a financial growth driver linked to decentralized prediction markets infrastructure
- Two distinct drivers of value creation operating in non-correlated domains: biotechnology innovation and forecasting infrastructure
Advancing Allocetra™ Macrophage Reprogramming Therapy
- Universal off-the-shelf cell therapy designed to restore macrophage homeostasis
- Positive Phase I/II knee osteoarthritis (OA) data demonstrating meaningful pain reduction and improved functional outcomes
- End-stage knee OA interim data showing significant average pain reduction across treated patients
- Pipeline expansion into additional OA indications including basal thumb OA and TMJ OA
- Psoriatic arthritis Phase I trial underway, targeting a market expected to exceed $20B by 2032
Experienced Leadership with Proven Execution
- Leadership team with experience across biotechnology, public markets, regulatory environments, and digital assets
- Management previously led the successful $590M exit of PROLOR Biotech and strategic partnerships with global pharmaceutical companies
- Board composition spanning global policy, biotechnology development, and digital infrastructure
Strengthened Capital Position
- Total treasury and treasury-related derivative assets were $2.31B, with $1.93B shareholder’s equity, and cash, cash equivalents, and short-term investments in digital assets: $30M at year end 2025
- Treasury strategy provides additional capital flexibility and long-term asset accumulation potential
- Capital structure designed to support continued clinical development while expanding treasury assets
Articles
May. 3, 2026 10 min read
Enlivex Ltd. (Nasdaq: ENLV), a quality longevity company, is the world's first publicly traded company to base its corporate treasury on a prediction market digital asset, operating a dual-strategy model that pairs clinical-stage immunotherapy development with a treasury built on the Rain Protocol, a decentralized prediction markets platform...
Read MoreClinical Trial Pipeline Stages
| Drug Name | Stage |
|---|---|
| Allocetra (Immunotherapy)DetailsTreatment of organ failure associated with Sepsis, Organ failure | Phase 2b |
| Allocetra (Immunotherapy)DetailsOsteoarthritis, Knee osteoarthritis | Phase 1/2 |
| Allocetra (Immunotherapy)DetailsOsteoarthritis, Basal thumb osteoarthritis | Phase 1/2 |
Sign Up For ENLV Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Enlivex Therapeutics (ENLV) is a client of RedChip Companies, Inc. ENLV agreed to pay RedChip Companies, Inc. an $8,000 monthly cash fee, beginning in February 2024, plus 25,000 warrants with an exercise price of $3.25 and 25,000 warrants with an exercise price of $4.25, for six month of investor awareness services. All warrants have a term of three years from date of issuance. ENLV also agreed to pay RedChip a one-time $50,000 fee for a national TV ad campaign aired September 11 to September 25, 2024, a one-time $37,500 fee for a national TV ad campaign aired October 14 to October 25, 2024, a one-time $37,500 fee for a national TV ad campaign aired December 4 to December 17, 2024, a one-time $42,500 fee for a national TV ad campaign aired February 26 to March 18, 2025, and a one-time $42,500 fee for a national TV ad campaign aired August 19 to September 2, 2025.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.